In the future, pharmacogenetic studies may be needed to introduce newer antiplatelet drugs that do not require CYP2C19 activation and may reduce the overall impact of clopidogrel resistance in patients with CAD. The gene discussed is CYP2C19; the disease is coronary artery disorder.